‘No more than a drop in the ocean’: this drug could end new HIV infections in Eswatini – why isn’t there enough? | Global development

In the high-stakes landscape of global HIV prevention, a paradox has emerged in Eswatini. Whereas the country stands on the precipice of eliminating latest infections, the arrival of lenacapavir—a biannual injectable pre-exposure prophylaxis (PrEP)—has been met with a supply chain bottleneck described by local health leaders as “not even a drop in the ocean.” As of April 2026, the disparity between clinical efficacy and logistical availability threatens to undermine one of the most significant biomedical advancements in the fight against the virus.

Key Clinical Takeaways:

• Mechanism of Action: Lenacapavir functions as a first-in-class capsid inhibitor, disrupting the HIV viral lifecycle at multiple stages, offering protection with only two injections per year.
• Supply Chain Disruption: Despite high efficacy, current stock levels in Eswatini cover less than 1% of the at-risk population, exacerbated by fluctuations in US foreign aid and manufacturing restrictions.
• Adherence Advantage: Clinical data suggests long-acting injectables significantly reduce the “adherence fatigue” associated with daily oral PrEP, particularly among key populations like sex workers and adolescent girls.

The Biological Promise Versus Logistical Reality

Lenacapavir represents a paradigm shift in prophylactic pharmacology. Unlike traditional antiretrovirals that target reverse transcriptase or protease, this molecule inhibits the HIV-1 capsid protein. This unique mechanism interferes with viral uncoating, DNA synthesis, and the assembly of new viral particles. In Phase 3 clinical trials, such as the PURPOSE 1 study, the drug demonstrated 100% efficacy in preventing HIV acquisition among cisgender women when administered subcutaneously every six months. This pharmacokinetic profile is critical for regions like Eswatini, where the HIV prevalence rate hovers near 27%.

However, the translation from peer-reviewed success to public health implementation faces severe friction. The country records approximately 4,000 new infections annually among a population of 1.2 million. While the government and partners like the Global Fund aim to distribute 6,000 doses in 2026, epidemiological modeling suggests this volume is insufficient to impact the reproduction number (R0) of the virus significantly. Dr. Nkululeko Dube, country programme director for the AIDS Healthcare Foundation Eswatini, highlights the stark mathematics: with nearly 3,000 people initiated on the regimen by March 2026, coverage remains critically low against the backdrop of high incidence.

Adherence and the Human Factor

The clinical utility of lenacapavir extends beyond viral suppression. it addresses the behavioral determinants of health. Daily oral PrEP, while effective, requires strict adherence to maintain therapeutic drug levels in the mucosal tissue. For marginalized groups, including sex workers and young women, the cognitive load of daily medication often competes with immediate survival needs. Interviews from the Lobamba clinic reveal that financial incentives often discourage condom use, increasing exposure risk. When daily pills are forgotten due to irregular schedules or stigma, protection wanes.

Long-acting injectables decouple protection from daily behavior. For patients like “Precious,” a sex worker navigating economic instability, a six-month injection offers a “set and forget” safety net that oral regimens cannot match. This shift reduces the morbidity associated with seroconversion and lowers the long-term burden on the healthcare system. However, the transition requires robust infrastructure. Patients initiating therapy require a loading dose of oral tablets alongside the initial injection to ensure rapid therapeutic concentrations, demanding coordinated pharmacy management that is currently straining under stock shortages.

“We are banking on lenacapavir to be the gamechanger. However, the coverage so far has been very, very, very low. But my impression is that interest is extremely high.” — Sindy Matse, Programme Manager, Eswatini National AIDS Programme.

Navigating Regulatory and Funding Barriers

The scarcity of lenacapavir is not merely a manufacturing issue but a complex interplay of intellectual property and geopolitical funding. In high-income markets, the annual cost per patient exceeds $28,000. Through tiered pricing agreements facilitated by the Medicines Patent Pool and the Global Fund, countries like Eswatini access the drug at approximately $60 per year. Yet, even at this reduced rate, supply is constrained. Manufacturer restrictions on direct sales to humanitarian organizations have drawn criticism from groups like Médecins Sans Frontières, who argue that such policies endanger vulnerable populations during the critical window before generic competition enters the market in 2027.

the volatility of international aid complicates procurement. Recent shifts in US health funding pacts have introduced uncertainty into the supply chain, forcing local ministries to pivot rapidly. For healthcare administrators and NGO leaders managing these procurements, the regulatory landscape is treacherous. Navigating these sudden shifts in EMA or FDA guidelines and funding stipulations often requires immediate supply chain audits. Pharmaceutical distributors and health ministries are increasingly retaining healthcare compliance attorneys to ensure that bilateral agreements do not create operational bottlenecks that stall life-saving deliveries.

Clinical Triage for At-Risk Populations

For the individual patient, the gap between availability and need creates a dangerous limbo. Young women and key populations, who account for three-quarters of new infections in the region, face barriers beyond mere stockouts. Stigma remains a potent virus; LGBTQ+ individuals and sex workers often report discrimination in mainstream facilities, deterring them from seeking PrEP until it is too late. Specialized care is essential. Patients struggling with adherence to oral regimens or those facing barriers to access should seek out vetted board-certified infectious disease specialists who can navigate the complexities of long-acting antiretroviral therapy and provide non-judgmental, comprehensive sexual health services.

The path forward relies on scaling production and normalizing access. Eswatini’s Minister of Health, Mduduzi Matsebula, has expressed confidence in ending AIDS as a public health threat by 2028, two years ahead of the global 2030 target. Achieving this requires that the “drop in the ocean” becomes a tide. As generic versions potentially lower the cost to $25 per year, the focus must shift from efficacy trials to equitable distribution networks.

The medical community watches Eswatini as a sentinel site for the future of HIV prevention. The science is settled; lenacapavir works. The challenge now is purely logistical and political. Until supply meets demand, the risk of new infections remains a manageable but unmitigated threat. For those currently unable to access these novel therapies, maintaining contact with local HIV/AIDS clinics remains the standard of care to monitor serostatus and explore alternative prophylactic options.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.